Higher CD34+ and CD3+ Cell Doses in the Graft Promote Long-Term Survival, and Have No Impact on the Incidence of Severe Acute or Chronic Graft-versus-Host Disease after In Vivo T Cell-Depleted Unrelated Donor Hematopoietic Stem Cell Transplantation in Children

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 10, 2010, Pages 1388-1401

  Kałwak, Krzysztof ^a   Porwolik, Julita ^a   Mielcarek, Monika ^a   Gorczyńska, Ewa ^a   Owoc Lempach, Joanna ^a   Ussowicz, Marek ^a   Dyla, Agnieszka ^a   Musiał, Jakub ^a   Paździor, Dominika ^a   Turkiewicz, Dominik ^a,b   Chybicka, Alicja ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CD34+ cell dose; CD3+ cell dose; Children; Graft content; Graft versus host disease; Hematopoietic stem cell transplantation; Unrelated donor

Indexed keywords

ALEMTUZUMAB; CD3 ANTIGEN; CD34 ANTIGEN; CYCLOSPORIN A; ETANERCEPT; FRESENIUS; HLA ANTIGEN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; TREOSULFAN; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADRENOLEUKODYSTROPHY; ADULT; AGE DISTRIBUTION; ALLELE; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC GRANULOMATOUS DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DONOR; FANCONI ANEMIA; FEMALE; GRISCELLI SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA TYPING; HODGKIN DISEASE; HUMAN; IN VIVO STUDY; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OMENN SYNDROME; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; PROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SEVERE COMBINED IMMUNODEFICIENCY; SURVIVAL TIME; T CELL DEPLETION; TREATMENT OUTCOME; WHOLE BODY RADIATION; WISKOTT ALDRICH SYNDROME;

ADOLESCENT; AGE FACTORS; ANTIGENS, CD3; ANTIGENS, CD34; BONE MARROW TRANSPLANTATION; CELL COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LEUKOCYTE REDUCTION PROCEDURES; LIVING DONORS; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956293276     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.04.001     Document Type: Article

References (30)

1. Miano M., Labopin M., Hartmann O., et al. Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007, 39:89-99.
2. Sedlacek P., Formankova R., Keslova P., et al. Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin. Bone Marrow Transplant 2006, 38:745-750.
3. Sedlacek P., Mejstrikova E., Formankova R., et al. Allo-SCT in children with high-risk leukemia using unmanipulated grafts from alternative donors. Bone Marrow Transplant 2008, 42:S10-S15.
4. Bensinger W.I., Clift R., Martin P., et al. Allogeneic peripheral blood progenitor cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996, 88:2794-2800.
5. Ottinger H.D., Beelen D.W., Scheulen B., Schaefer U.W., Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996, 88:2775-2779.
6. Allogeneic peripheral blood stem cell compared bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of 9 randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem cell Trialists' Collaborative Group.
7. Ringden O., Remberger M., Runde V., et al. Peripheral blood stem cell transplantation from unrelated donors; a comparison with marrow transplantation. Blood 1999, 94:455-464.
8. Remberger M., Ringden O., Blau I.W., et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001, 98:1739-1745.
9. Remberger M., Beelen D.W., Fauser A., Basara N., Basu O., Ringden O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation using unrelated donors. Blood 2005, 105:548-551.
10. Elmaagacli A., Basoglu S., Peceny R., et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002, 99:1130-1135.
11. Garderet L., Labopin M., Gorin N.C., et al. Patients with acute lymphoblastic leukemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplant 2003, 31:23-29.
12. Meisel R., Laws H., Balzer S., et al. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies. Biol Blood Marrow Transplant 2007, 13:1338-1345.
13. Nakamura R., Auayporn N., Smith D.D., et al. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: Higher CD34+ cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant 2008, 14:449-457.
14. Remberger M., Mattson J., Hassan Z., et al. Risk factors for acute graft-versus-host disease grade II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study. Bone Marrow Transplant 2008, 41:399-405.
15. Baron F., Maris M.B., Storer B.E., et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005, 19:822-828.
16. Pulsipher M.A., Chitphakdithai P., Logan B.R., et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009, 114:2606-2616.
17. Collins N.H., Gee A.P., Durett A.G., et al. The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes. Biol Blood Marrow Transplant 2010, 16:253-262.
18. Jacobsohn D.A. Acute graft-versus-host disease in children. Bone Marrow Transplant 2008, 41:215-221.
19. Akpek G. Clinical grading in chronic graft-versus-host disease: is it time for change?. Leuk Lymphoma 2002, 43:1211-1220.
20. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1858, 53:457-481.
21. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
22. Cox D.R. Regression models and life tables. J R Stat Soc 1972, 34:187-220.
23. Scrucca L., Santucci A., Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010 Jan 11, [Epub ahead of print].
24. Davies S.M., Wang T., Wang T., et al. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 2009, 15:360-366.
25. Heimfeld S. HLA-identical stem cell transplantation: is there an optimal CD34 cell dose?. Bone Marrow Transplant 2003, 31:839-845.
26. Zaucha J.M., Gooley T., Bensinger W.I., et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001, 98:3221-3227.
27. Przepiorka D., Anderlini P., Saliba R., et al. Chronic graft-versus host disease after allogeneic blood stem cell transplantation. Blood 2001, 98:1695-1700.
28. Cao T.M., Wong R.M., Sheehan K., et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol 2005, 33:279-285.
29. Kernan N.A., Bartsch G., Ash R.C., et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993, 328:593-602.
30. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high resolution matching on unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004, 104:1923-1930.